The effect of surface area expansion with pericardial membrane (preclude) in Ahmed glaucoma valve implant surgery.
To compare the efficacy of Ahmed glaucoma valve (AGV) implant with and without surface area expansion using pericardial membrane (Preclude) in the treatment of complicated glaucoma. Ten eyes of AGV implant surgery using pericardial membrane (Preclude) that were designed to have surface area of 300 mm (e-AGV group) and 10 eyes of AGV implant surgery without surface area extension (AGV group) were enrolled in this prospective, randomized controlled trial study. Two (20%) of 10 eyes in the e-AGV group, and 8 (80%) of 10 eyes in the AGV group experienced the hypertensive phase (P = 0.007). Complete success rate was 90% in the e-AGV group and 70% in the AGV group (P = 0.291). Mean number of preoperative antiglaucoma medication was 2.4 +/- 0.5 and 1.9 +/- 0.3 for the e-AGV and AGV groups, respectively, and that of postoperative antiglaucoma medication was 0.1 +/- 0.3 and 0.4 +/- 0.7 for the e-AGV and AGV groups, respectively, at final follow-up (P = 0.229). Surface area expansion with pericardial membrane (Preclude) in AGV implant surgery resulted in a statistically significantly lower rate of hypertension without causing any postoperative complications.